What happened with VCEL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of Vericel’s revenue comes from MACI, an implant for certain knee cartilage defects in adults. A surgeon sends the patient’s cartilage biopsy to Vericel, which grows the cells and places them on a collagen membrane for implantation if treatment proceeds. MACI reaches patients mainly through specialty pharmacies Orsini and AllCare, with payment generally coming from private insurers or government payers. Vericel also sells directly to hospitals. Coverage must be confirmed before shipment; the pharmacies handle collections, but Vericel bears the risk of nonpayment.
The smaller burn-care business sells Epicel, a permanent skin replacement made from the patient’s own cells, directly to hospitals and burn centers. It also sells NexoBrid, an enzyme treatment that removes dead burn tissue, to specialty distributors for resale to those facilities. MediWound manufactures and supplies NexoBrid under exclusive North American license and supply agreements.
The business depends on payer reimbursement and reliable manufacturing supplies: Matricel is the sole supplier of MACI’s collagen membrane, and Vericel must comply with its MediWound agreements to retain NexoBrid’s exclusive rights. Vericel may promote its products only for FDA-approved uses. Epicel’s humanitarian-use approval also generally requires a facility’s institutional review board to approve its use.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Vericel’s results depend mainly on MACI procedure growth and reimbursement, while manufacturing relies on collagen membranes supplied exclusively by Matricel.
Regentis Biomaterials Ltd. could challenge Vericel’s MACI with GelrinC, a ready-made, cell-free implant for focal knee cartilage defects, but U.S. competition depends on approval. Unlike MACI, which Vericel makes from a patient’s cartilage biopsy, GelrinC remains in development; watch its U.S. approval and reimbursement progress.
Vericel depends on MediWound Ltd. to manufacture and license NexoBrid, the burn treatment it sells through specialty distributors to hospitals and burn centers in North America. MediWound receives supply payments, royalties and potential sales milestones from Vericel; watch NexoBrid supply pricing, which can rise under their agreements.
Ocugen, Inc.’s NeoCart cartilage-repair program could compete for the market served by Vericel’s MACI, but only if development succeeds and it wins approval. Ocugen has not earned revenue from its product candidates, so NeoCart’s development and approval news matter more for this tie than current sales.
Smith & Nephew plc shares exposure to sports-medicine surgery demand with Vericel: it sells sports-medicine implants and arthroscopic equipment to surgeons who perform procedures such as MACI knee cartilage repair. It is a way to follow demand among those surgeons, rather than a direct readout of MACI sales.
CONMED Corporation shares sports-medicine surgery demand with Vericel’s MACI cartilage-repair business. It sells orthopedic implants and equipment that lets surgical teams see inside the joint and manage fluids, so its orthopedic business is the relevant demand signal, not its general-surgery sales.
Integra LifeSciences Holdings competes in Vericel’s smaller burn-care business: its templates for rebuilding skin and Vericel’s Epicel both serve burn surgeons treating serious skin loss. For this comparison, watch Integra’s skin-repair products rather than its neurosurgery business.
Integra LifeSciences Holdings earningsIART
Integra LifeSciences’ skin-repair sales will show how demand is changing in the serious-burn market it shares with Vericel’s Epicel.
Focus on Integra’s skin-repair products, not its neurosurgery business. Steady or stronger activity in those products would suggest the serious-burn market that Epicel serves remains supportive, but would not establish that Epicel sales are growing. Weaker activity would point to a less supportive market for Vericel’s smaller burn business, or possible competitive pressure.
CONMED Corporation earningsCNMD
CONMED’s orthopedic business will show how sports-medicine surgery demand is faring, offering a market signal for Vericel’s MACI knee-cartilage repair business.
Watch CONMED’s orthopedic business, not its general-surgery sales. Steady or rising orthopedic activity would suggest a supportive sports-medicine surgery backdrop for potential MACI patients and procedures; weakness could mean fewer favorable opportunities for Vericel’s implants. CONMED sales are not a measure of MACI use, so treat them as a market signal, not proof of Vericel’s results.
Vericel Corporation earningsThis company
Vericel Corporation’s report will show whether MACI implant sales can keep spreading manufacturing costs across more revenue and lift profit.
Read MACI revenue alongside gross profit. If revenue rises and gross profit rises faster, more sales are spreading manufacturing costs, which are mainly labor and facility costs; slower revenue growth, or gross profit failing to keep pace, would show that volume, pricing or costs are limiting that benefit. The comparison tells readers whether growth in Vericel’s main product is translating into stronger product profitability.
MediWound Ltd. earningsMDWD
MediWound’s report will show how NexoBrid supply and supply pricing are developing, affecting Vericel’s sales to North American hospitals and burn centers.
Read MediWound’s NexoBrid supply alongside its supply pricing. Reliable supply without higher pricing would leave Vericel better placed to serve distributors, hospitals and burn centers in North America; disrupted supply or higher prices could limit availability or increase Vericel’s product-cost pressure. The combination shows whether NexoBrid growth can translate into sustainable sales for Vericel.
